Drug Profile

PAb 001

Alternative Names: anti-MUC1 antibody-drug conjugate - Peptron/Qilu Pharmaceutical; PAb001; PAb001_ADC

Latest Information Update: 01 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Peptron
Developer Peptron; Qilu Pharmaceutical
Class Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Mucin 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Jun 2026 Preclinical development is still ongoing in South Korea and China (Peptron Pipeline, May 2026)
28 Apr 2025 No recent reports of development identified for preclinical development in Cancer in China
28 Apr 2025 No recent reports of development identified for preclinical development in Cancer in South Korea

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com